|
| |
Thrombotargets Corp. and Magellan Bioscience Group, Inc. to collaborate on
identification of novel hits from both marine derivate and natural products.
Companies Sign a Collaborative Agreement. Durham, June 13th, 2007.
Thrombotargets Corporation and Magellan Bioscience Group, Inc. today announced
the formation of drug discovery joint venture.
Under the terms of this agreement, Magellan Bioscience Group, Inc. will provide
to Thrombotargets its compounds and extracts from fermentation broths of
marine-isolated microorganisms to be screened through the revolutionary High
Throughput Screening of Pathway Activity, BIOPLATFORMSCREEN™ technology. This
modified HTS platforms allows to both Thrombotargets and partners to identify
novel hits for entire Pathways regulating a certain biological activity.
About Thrombotargets Group:
Thrombotargets (
www.thrombotargets.com ) is a privately held group of Biotech companies
focused in the discovery and development of innovative drugs in Haemostasis,
Thrombosis and Atherosclerosis. The company has a number of potential new drugs
in development internally, and its proprietary targets and innovative uHTS
platforms are used for internal drug discovery programs, and also for
out-licensing and partnering of new research projects.
About Magellan:
Magellan BioScience Group, Inc. (
www.magellanbioscience.com ),
based in Saint Petersburg Tampa, Florida, (USA) a., is a privately held
innovative biotechnology company focused on the discovery of novel classes of
therapeutic candidates. Magellan is using its integrated platform technologies
to isolate and identify new biologically active compounds. The company believes
that its library of marine microbes will be the next source of drug discovery
for the pharmaceutical industry. Magellan aims to develop and optimize drug
candidates to treat cancer, infectious diseases, and inflammation.
Contact:
Luis Caveda Ph.D.
Thrombotargets Corp.
Executive Vice President
luiscaveda@thrombotargets.com
| |
|
